Polynovo Ltd (PNV.AX) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Australia · ISIN AU000000PNV0

Price
0.91 AUD
Market cap
631.87 m AUD
P/E (2026)
86.07
P/S (2026)
4.40
Dividend yield
0.00 %
Net margin
5.11 %
Return on equity (ROE)
8.09 %
Return on assets (ROA)
5.54 %

Polynovo Ltd financials

Fiscal year20252026
Revenue127.24 m AUD143.71 m AUD
Gross profit122.05 m AUD46.99 m AUD
Operating income4.48 m AUD10.47 m AUD
EBIT7.76 m AUD10.47 m AUD
Net income13.21 m AUD7.34 m AUD
Diluted EPS – continuing operations0.02 AUD0.01 AUD

Full history since 1999, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Polynovo Ltd

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.